Prodrug strategies in ocular drug delivery

Medicinal Chemistry

Volumn 8, Issue 4, 2012, Pages 753-768

  Barot, Megha ^a   Bagui, Mahuya ^a   Gokulgandhi, Mitan R ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Drug delivery; Prodrug; Receptor; Transporter

Indexed keywords

ACICLOVIR; ADRENERGIC RECEPTOR BLOCKING AGENT; AGENTS ACTING ON THE EYE; ALPRENOLOL; ANANDAMIDE; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CANNABINOID; CARBONATE DEHYDRATASE INHIBITOR; DEXAMETHASONE; DIPEPTIDE; DIPIVEFRINE; ETACRYNIC ACID; FLUOROURACIL; GANCICLOVIR; LATANOPROST; OXAZOLIDINE DERIVATIVE; PHENYLEPHRINE; PRODRUG; PROPRANOLOL; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2 ALPHA DERIVATIVE; SA 12590; SA 9000; STEROID; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE;

ADD ON THERAPY; ADENOVIRUS; ARTICLE; CELL PROLIFERATION; CHEMICAL MODIFICATION; CHOLINERGIC ACTIVITY; CONJUNCTIVAL HYPEREMIA; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DIFFUSION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; ENZYME STABILITY; EYE ALLERGY; HERPES VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; POXVIRUS; PRIORITY JOURNAL; RETINITIS; VITREORETINOPATHY;

ADMINISTRATION, OPHTHALMIC; DRUG DELIVERY SYSTEMS; HUMANS; PRODRUGS;

EID: 84863765854     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340612801216283     Document Type: Article

References (197)

1. Liederer, B. M.; Borchardt, R. T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci., 2006, 95(6), 1177-95.
2. Testa, B.; Mayer, J. M. Hydrolysis in Drug and Prodrug Metabolism, Wiley-VCH Verlag GmbH, Weinheim, 2003.
3. Kwatra, D.; Vaishya R.; Gaudana, R.; Jwala, J. In: Prodrugs and Targeted Delivery Towards Better ADME Properties; Jarkko Rautio, Ed.; Wiley-VCH: Germany, 2011; Vol. 47, pp. 181-201.
4. Faulkner, R.; Sharif, N. A.; Orr, S.; Sall, K.; Dubiner, H.; Whitson, J. T.; Moster, M.; Craven, E. R.; Curtis, M.; Pailliotet, C.; Martens, K.; Dahlin, D. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topcal ocular doses of LUMIGAN or TRAVATAN. J. Ocul. Pharmacol. Ther., 2010, 26(2), 147-56.
5. Fukano, Y.; Kawazu, K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug. Metab. Dispos., 2009. 37(8), 1622-34.
6. Majumdar, S.; Hingorani, T.; Srirangam, R.; Gadepalli, R. S.; Rimoldi, J. M.; Repka, M. A. Transcorneal permeation of L-and Daspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Pharm. Res., 2009, 26(5), 1261-9.
7. Alexander, J.; Cargill, R.; Michelson, S. R.; Schwam, H. (Acyloxy) alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J. Med. Chem., 1988, 31(2), 318-22.
8. Lallemand, F.; Varesio, E.; Felt-Baeyens, O.; Bossy, L.; Hopfgartner, G.; Gurny, R. Biological conversion of a watersoluble prodrug of cyclosporine A. Eur. J. Pharm. Biopharm., 2007, 67(2), 555-61.
9. Juntunen, J.; Jarvinen, T.; Niemi, R. In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs. J. Pharm. Pharmacol., 2005, 57(9), 1153-7.
10. Mäntylä, A.; Garnier, T.; Rautio, J.; Nevalainen, T.; Vepsälainen, J.; Koskinen, A.; Croft, S. L.; Järvinen, T. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J. Med. Chem., 2004, 47(1), 188-95.
11. Juntunen, J.; Huuskonen, J.; Laine, K.; Niemi, R.; Taipale, H.; Nevalainen, T.; Pate, D. W.; Jarvinen, T. Anandamide prodrugs. 1. Water-soluble phosphate esters of arachidonylethanolamide and Rmethanandamide. Eur. J. Pharm. Sci., 2003, 19(1), 37-43.
12. Shimazaki, A.; Kirihara, T.; Rao, P. V.; Tajima, H.; Matsugi, T.; Epstein, D. L. Effects of the new ethacrynic acid oxime derivative SA12590 on intraocular pressure in cats and monkeys. Biol. Pharm. Bull., 2007, 30(8), 1445-9.
13. Farag, H. H.; Wu, W. M.; Barros, M. D.; Somogyi, G.; Prokai, L.; Bodor, N. Ocular-specific chemical delivery systems of betaxolol for safe local treatment of glaucoma. Drug Des. Discov., 1997, 15(2), 117-30.
14. Järvinen, T.; Niemi, R. In: Prodrug Approaches to Ophthalmic Drug Delivery; Stella, V.; Borchardt, R.; Hageman, M.; Oliyai, R.; Maag, H.; Tilley, J.; Springer: New York, 2007; Vol. V, pp. 125-155.
15. Neises B.; Angew W. S. Simple method for the esterification of carboxylic acids bernhard neises and wolfgang steglich. Chem. Int. Ed., 1978, 17, 522.
16. Hussain, A.; Truelove, J. E. Prodrug approaches to enhancement of physicochemical properties of drugs IV: novel epinephrine prodrug. J. Pharm. Sci., 1976, 65(10), 1510-2.
17. Wei, C. P.; Anderson, J. A.; Leopold, I. Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine. Invest. Ophthalmol. Vis. Sci., 1978, 17(4), 315-21.
18. Mandell, A. I.; Stentz, F.; Kitabchi, A. E. Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmology, 1978, 85(3), 268-75.
19. Niemi, R.; Huuskonen, J.; Laine, K.; Jarvinen, T. Synthesis, hydrolysis, and intraocular pressure lowering effects of fadolmidine prodrugs. Int. J. Pharm., 2005, 295(1-2), 121-7.
20. Chien, D. S.; Schoenwald, R. D. Improving the ocular absorption of phenylephrine. Biopharm. Drug Dispos., 1986, 7(5), 453-62.
21. Kawakami, S.; Ohshima, N.; Hirayama, R.; Al, M. H.; Kitahara, T.; Sakaeda, T.; Mukai, T.; Nishida, K.; Nakamura, J.; Nakashima, M.; Sasaki, H. Biodistribution and pharmacokinetics of O-palmitoyl tilisolol, a lipophilic prodrug of tilisolol, after intravenous administration in rats. Biol. Pharm. Bull., 2002, 25(8), 1072-6.
22. Chang, S. C.; Bundgaard, H.; Buur, A.; Lee, V. H. Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load. Invest. Ophthalmol. Vis. Sci., 1987, 28(3), 487-91.
23. Suhonen, P.; Jarvinen, T.; Koivisto, S.; Urtti, A. Different effects of pH on the permeation of pilocarpine and pilocarpine prodrugs across the isolated rabbit cornea. Eur. J. Pharm. Sci., 1998, 6(3), 169-76.
24. Jarvinen, T.; Auriola, S.; Peura, P.; Suhonen, P.; Urtti, A.; Vepsalainen, J. Synthesis and identification of pilocarpic acid diesters, prodrugs of pilocarpine. J. Pharm. Biomed. Anal., 1991, 9(6), 457-64.
25. Woltersdorf, O. W., Jr.; Schwam, H.; Bicking, J. B.; Brown, S. L.; deSolms, S. J.; Fishman, D. R.; Graham, S. L.; Gautheron, P. D.; Hoffman, J. M.; Larson, R. D. Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide. J. Med. Chem., 1989, 32(11), 2486-92.
26. Russo, A.; Riva, I.; Pizzolante, T.; Noto, F.; Quaranta, L. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin. Ophthalmol., 2008, 2(4), 897-905.
27. Macha, S.; Duvvuri, S.; Mitra, A. K. Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. Curr. Eye Res., 2004, 28(2), 77-84.
28. Gaudana, R.; Parenky, A.; Vaishya, R.; Samanta, S. K.; Mitra, A. K. Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation. J. Microencapsul. 2011, 28(1), 10-20.
29. Civiale, C.; Bucaria, F.; Piazza, S.; Peri, O.; Miano, F.; Enea, V. Ocular permeability screening of dexamethasone esters through combined cellular and tissue systems. J. Ocul. Pharmacol. Ther., 2004, 20(1), 75-84.
30. Duvvuri, S.; Majumdar, S.; Mitra, A. K. Role of metabolism in ocular drug delivery. Curr. Drug Metab., 2004, 5(6), 507-15.
31. Bundgaard, H.; Buur, A.; Chang, S. C.; Lee, V. H. L. Timolol prodrugs: synthesis, stability and lipophilicity of various alkyl, cycloalkyl and aromatic esters of timolol. Int. J. Pharm., 1988, 46, 77-88.
32. Tirucherai, G. S.; Dias, C.; Mitra, A. K. Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J. Ocul. Pharmacol. Ther., 2002, 18(6), 535-48.
33. Camras, C. B.; Siebold, E. C., Lustgarten, J. S.; Serle, J. B.; Frisch, S. C.; Podos, S. M.; Bito, L. Z. Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology, 1989, 96(9), 1329-1337.
34. Camber O.; Edman P.; Olsson L. I. Permeability of prostaglandin F2α and prostaglandin F2α esters across cornea in vitro. Int. J. Pharm., 1986, 29, 259-266.
35. Villumsen, J.; Alm, A.; Soderstrom, M. Prostaglandin F2 alphaisopropylester eye drops: effect on intraocular pressure in openangle glaucoma. Br. J. Ophthalmol., 1989, 73(12), 975-9.
36. Suzuki, E. R.; Suzuki, C. L. Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations. Clin. Ophthalmol., 2010, 4, 1165-71.
37. Melamed, S. Neuroprotective properties of a synthetic docosanoid, unoprostone isopropyl: clinical benefits in the treatment of glaucoma. Drugs Exp. Clin. Res., 2002, 28(2-3), 63-73.
38. Sjoquist, B.; Stjernschantz, J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthalmol., 2002, 47 Suppl 1, S6-12.
39. Camber, O.; Edman, P. Factors influencing the corneal permeability of prostaglandin F2α and its isopropyl ester in vitro. Int. J. Pharm., 1987, 37, 27-32.
40. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: design and clinical applications. Nat. Rev. Drug. Discov., 2008, 7(3), 255-70.
41. McComb, R. B.; Bowers, Jr G. N.; Posen, S. Alkaline Phosphatase, Plenum Press, New York and London, 1979.
42. Juntunen, J.; Vepsalainen, J.; Niemi, R.; Laine, K.; Jarvinen, T. Synthesis, in vitro evaluation, and intraocular pressure effects of water-soluble prodrugs of endocannabinoid noladin ether. J. Med. Chem., 2003, 46(23), 5083-6.
43. Reddy, I. K. Ocular theraputics and drug delivery: a multidisciplinary approach, 1st ed.; CRC Press, 1995.
44. Li, Z.; Bitha, P.; Lang, S. A.; Lin, Y. I. Synthesis of (alkoxycarbonyloxy) methyl, (acyloxy) methyl and (oxodioxolenyl) methyl carbamates as bioreversible prodrug moieties for amines. Bioorg. Med. Chem. Lett., 1997, 7(22), 2909-2912.
45. Alexander, J.; Cargill, R.; Michelson, S. R.; Schwam, H. (Acyloxy) alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J. Med. Chem., 1988, 31(2), 318-22.
46. Gogate, U. S.; Repta, A. J.; Alexander, J. N-(Acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. I. kinetics and mechanism of degradation in aqueous solutions. Int. J. Pharm., 1987, 40, 235-248.
47. Gogate, U. S.; Repta, A. J. N-(Acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. II. esterase-catalysed release of parent amines from model prodrugs. Int. J. Pharm., 1987, 40, 249-255.
48. Simplício, A. L.; Clancy, J. M.; Gilmer, J. F. Prodrugs for amines. Molecules, 2008, 13(3), 519-47.
49. Bodor, N.; Elkoussi, A. Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime-a new potential antiglaucoma agent. Pharm. Res., 1991, 8(11), 1389-95.
50. Manna, F.; Chimenti, F.; Bolasco, A.; Lena, R.; Filippelli, A.; Falciani, M.; Fontana, M. Beta-adrenoreceptor blocking heterocyclic oximes and ethers. Farmaco., 1996, 51(11), 699-706.
51. Bodor, N., Farag, H. H., Somogyi, G., Wu, W. M., Barros, M. D., Prokai, L. Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs. J. Ocul. Pharmacol. Ther., 1997, 13(5), 389-403.
52. Bodor, N. Retrometabolic approaches for drug design and targeting. Pharmazie, 1997, 52(7), 491-4.
53. Polgar, P.; Bodor, N. Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs. Life Sci., 1995, 56(14), 1207-13.
54. Bodor, N.; Prokai, L. Site-and stereospecific ocular drug delivery by sequential enzymatic bioactivation. Pharm. Res., 1990, 7(7), 723-5.
55. Bodor, N.; ElKoussi, A.; Kano, M.; Nakamura, T. Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents. J. Med. Chem., 1988, 31(1), 100-6.
56. Bodor, N.; Buchwald, P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J., 2005, 7(4), E820-33.
57. Bundgaard, H.; Johansen, M. Pro-drugs as drug delivery systems XX. Oxazolidines as potential pro-drug types for β-aminoalcohols, aldehydes or ketones. Int. J. Pharm., 1982, 10(2), 165-175.
58. Walker, R. B.; Dholakia, V. N.; Brasfield, K. L.; Bakhtiar, R. Effect of hydroxypropyl-beta-cyclodextrin on the central stimulant activity of (-)-ephedrine and an oxazolidine prodrug in rats. General Pharmacol., 1998, 30(5), 725-731.
59. Hu, L. In: Prodrug approaches to drug delivery; Wang, B.; Siahaan, T. J.; Soltero, R.; John Wiley & Sons Inc., 2005; pp. 125-165.
60. Miller-Meeks, M. J.; Farrell, T. A.; Munden, P. M.; Folk, J. C.; Rao, C.; Schoenwald, R. D. Phenylephrine prodrug. report of clinical trials. Ophthalmology, 1991, 98(2), 222-6.
61. Buur, A.; Bundgaard, H. Prodrugs as drug delivery systems. XXVIII. Structural factors influencing the rate of hydrolysis of oxazolidines-a potential prodrug type. Int. J. Pharm., 1984, 18(3), 325-334.
62. Schoenwald, R. D.; Folk, J. C.; Kumar, V.; Piper J. G. In Vivo comparison of phenylephrine and phenylephrine oxazolidine instilled in the monkey eye. J. Ocul. Pharmacol. Ther., 1987, 3(4), 333-340.
63. Chien, D. S.; Schoenwald, R. D. Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes. Pharm. Res., 1990, 7(5), 476-83.
64. Johansen. M.; Bundgaard, H. Prodrugs as drug delivery systems XXV: hydrolysis of oxazolidines-a potential new prodrug type. J. Pharm. Sci., 1983, 72(11), 1294-8.
65. Larsen, J. D.; Bundgaard, H.; Lee, V. H. Prodrug forms for the sulfonamide group. II. Water-soluble amino acid derivatives of Nmethylsulfonamides as possible prodrugs. Int. J. Pharm., 1988, 47, 103-110.
66. Lopes, F.; Moreira, R.; Iley, J. Acyloxymethyl as a drug protecting group. Part 6: N-acyloxymethyl-and N-[(aminocarbonyloxy) methyl]sulfonamides as prodrugs of agents containing a secondary sulfonamide group. Bioorg. Med. Chem., 2000, 8(4), 707-16.
67. Larsen, J. D.; Bundgaard, H. Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamidines, Nsulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharm., 1987, 37(1-2), 87-95.
68. Larsen J. D.; Bundgaard, H. Prodrug forms for the sulfonamide group. III. Chemical and enzymatic hydrolysis of various Nsulfonyl imidates-a novel prodrug form for a sulfonamide group or an ester function. Int. J. Pharm., 1989, 51, 27-38.
69. Bundgaard, H.; Larsen, J. D. N-sulfonyl imidates as a novel prodrug form for an ester function or a sulfonamide group. J. Med. Chem., 1988, 31(11), 2066-9.
70. Larsen, J. D.; Bundgaard, H. Prodrug forms for the sulfonamide group. IV. Kinetics of hydrolysis of N-sulfonyl pseudourea derivatives. Acta Pharm. Nord., 1989, 1(1), 31-40.
71. Pavan-Langston, D.; North, R. D., Jr.; Geary, P. A.; Kinkel, A. Intraocular penetration of the soluble antiviral, Ara AMP. Arch. Ophthalmol., 1976, 94(9), 1585-8.
72. Qiu, Y.; Schoenwald, R. D.; Guillory, J. K. Physicochemical characterization of high-and low-melting phenylephrine oxazolidines. Pharm. Res., 1993, 10(10), 1507-15.
73. Mincione, F.; Scozzafava, A.; Supuran, C. T. The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. Curr. Top. Med. Chem., 2007, 7(9), 849-54.
74. Lee, V. H. Membrane transporters. Eur. J. Pharm. Sci., 2000, 11 Suppl 2, S41-50.
75. Tsuji, A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther. Drug Monit., 1998, 20(5), 588-90
76. Cannon, R. D.; Lamping, E.; Holmes, A. R.; Niimi, K.; Baret, P. V.; Keniya, M. V.; Tanabe, K.; Niimi, M.; Goffeau, A.; Monk, B. C. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev., 2009, 22(2), 291-321.
77. Kim, R. B. Drug efflux transporters and antiviral drug therapy. Expert. Opin. Ther. Targets., 2000, 4, 439-446.
78. Dilger, K.; Schwab, M.; Fromm, M. F. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump Pglycoprotein. Inflamm. Bowel Dis., 2004, 10(5), 578-83.
79. Barot, M.; Gokulgandhi, M. R.; Haghnegahdar, M.; Dalvi, P.; Mitra, A. K. Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells. J. Ocul. Pharmacol. Ther., 2011, 27(6), 553-9.
80. Marquez, B.; Caceres, N. E.; Mingeot-Leclercq, M. P.; Tulkens, P. M.; Van Bambeke, F. Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob. Agents Chemother., 2009, 53(6), 2410-6.
81. Katragadda, S.; Talluri, R. S.; Mitra, A. K. Modulation of Pglycoproteinmediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea. J. Ocul. Pharmacol. Ther., 2006, 22(2), 110-20.
82. Jain, R.; Majumdar, S.; Nashed, Y.; Pal, D.; Mitra, A. K. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol. Pharm., 2004, 1(4), 290-9.
83. Duvvuri, S.; Gandhi, M. D.; Mitra, A. K. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr. Eye. Res., 2003, 27(6), 345-53.
84. Katragadda, S.; Jain, R.; Kwatra, D.; Hariharan, S.; Mitra, A. K. Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. Int. J. Pharm., 2008, 362(1-2), 93-101.
85. Anand, B. S.; Katragadda, S.; Nashed, Y. E.; Mitra, A. K. Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Curr. Eye Res., 2004, 29, (2-3), 153-66.
86. Nashed, Y. E.; Mitra, A. K. Synthesis and characterization of novel dipeptide ester prodrugs of acyclovir. Spectrochim. Acta. A Mol. Biomol. Spectrosc., 2003, 59(9), 2033-9.
87. Janoria, K. G.; Boddu, S. H.; Natesan, S.; Mitra, A. K. Vitreal pharmacokinetics of peptide-transporter-targeted prodrugs of ganciclovir in conscious animals. J. Ocul. Pharmacol. Ther., 2010, 26(3), 265-71.
88. Kansara, V.; Hao, Y.; Mitra, A. K. Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina. J. Ocul. Pharmacol. Ther., 2007, 23(4), 321-34.
89. Patel, K.; Trivedi, S.; Luo, S.; Zhu, X.; Pal, D.; Kern, E. R.; Mitra, A. K. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int. J. Pharm., 2005, 305(1-2), 75-89.
90. Anand, B.; Nashed, Y.; Mitra, A. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Curr. Eye Res., 2003, 26(3-4), 151-63.
91. Balakrishnan, A.; Jain-Vakkalagadda, B.; Yang, C.; Pal, D.; Mitra, A. K. Carrier mediated uptake of L-tyrosine and its competitive inhibition by model tyrosine linked compounds in a rabbit corneal cell line (SIRC)-strategy for the design of transporter/receptor targeted prodrugs. Int. J. Pharm., 2002, 247(1-2), 115-25.
92. Hosoya, K.; Kondo, T.; Tomi, M.; Takanaga, H.; Ohtsuki, S.; Terasaki, T. MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm. Res., 2001, 18(12), 1669-76.
93. Tsuji, A.; Tamai, I.; Nakanishi, M.; Terasaki, T.; Hamano, S. Intestinal brush-border transport of the oral cephalosporin antibiotic, cefdinir, mediated by dipeptide and monocarboxylic acid transport systems in rabbits. J. Pharm. Pharmacol., 1993, 45(11), 996-8.
94. Janoria, K. G.; Boddu, S. H.; Wang, Z.; Paturi, D. K.; Samanta, S.; Pal, D.; Mitra, A. K. Vitreal pharmacokinetics of biotinylated ganciclovir: role of sodium-dependent multivitamin transporter expressed on retina. J. Ocul. Pharmacol. Ther., 2009, 25(1), 39-49.
95. Dalpiaz, A.; Pavan, B.; Scaglianti, M.; Vitali, F.; Bortolotti, F.; Biondi, C.; Scatturin, A.; Manfredini, S. Vitamin C and 6-aminovitamin C conjugates of diclofenac: synthesis and evaluation. Int. J. Pharm., 2005, 291(1-2), 171-81.
96. Manfredini, S.; Vertuani, S.; Pavan, B.; Vitali, F.; Scaglianti, M.; Bortolotti, F.; Biondi, C.; Scatturin, A.; Prasad, P.; Dalpiaz, A. Design, synthesis and in vitro evaluation on HRPE cells of ascorbic and 6-bromoascorbic acid conjugates with neuroactive molecules. Bioorg. Med. Chem., 2004, 12(20), 5453-63.
97. Dalpiaz, A.; Pavan, B.; Scaglianti, M.; Vitali, F.; Bortolotti, F.; Biondi, C.; Scatturin, A.; Tanganelli, S.; Ferraro, L.; Prasad, P.; Manfredini, S. Transporter-mediated effects of diclofenamic acid and its ascorbyl pro-drug in the in vivo neurotropic activity of ascorbyl nipecotic acid conjugate. J. Pharm. Sci., 2004, 93(1), 78-85.
98. Manfredini, S.; Pavan, B.; Vertuani, S.; Scaglianti, M.; Compagnone, D.; Biondi, C.; Scatturin, A.; Tanganelli, S.; Ferraro, L.; Prasad, P.; Dalpiaz, A. Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to increase neurotropic activity. J. Med. Chem., 2002, 45(3), 559-62.
99. Anand, B. S.; Mitra, A. K. Mechanism of corneal permeation of Lvalyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm. Res., 2002, 19(8), 1194-202.
100. Basu, S. K.; Haworth, I. S.; Bolger, M. B.; Lee, V. H. Protondriven dipeptide uptake in primary cultured rabbit conjunctival epithelial cells. Invest. Ophthalmol. Vis. Sci., 1998, 39(12), 2365-73.
101. Majumdar, S.; Macha, S.; Nashed, Y.; Mitra, A. K. Expression of peptide transporters on the rabbit retina: A strategy to improve retinal delivery of ganciclovir. Lett. Drug Des. Discov., 2004, 1, 73-77.
102. Ocheltree, S. M.; Keep, R. F.; Shen, H.; Yang, D.; Hughes, B. A.; Smith, D. E. Preliminary investigation into the expression of protoncoupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes. Pharm. Res., 2003, 20(9), 1364-72.
103. Atluri, H.; Anand, B. S.; Patel, J.; Mitra, A. K. Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration. Exp. Eye. Res., 2004, 78(4), 815-22.
104. Takahashi, H.; Kaminski, A. E.; Zieske, J. D. Glucose transporter 1 expression is enhanced during corneal epithelial wound repair. Exp. Eye Res., 1996, 63(6), 649-59.
105. Gurses, I.; Doganay, S.; Mizrak, B. Expression of glucose transporter protein-1 (Glut-1) in ocular surface squamous neoplasia. Cornea, 2007, 26(7), 826-30.
106. Gherzi, R.; Melioli, G.; De Luca, M.; D'Agostino, A.; Guastella, M.; Traverso, C. E.; D'Anna, F.; Franzi, A. T.; Cancedda, R. High expression levels of the "erythroid/brain" type glucose transporter (GLUT1) in the basal cells of human eye conjunctiva and oral mucosa reconstituted in culture. Exp. Cell Res., 1991, 195(1), 230-6.
107. Mantych, G. J.; Hageman, G. S.; Devaskar, S. U. Characterization of glucose transporter isoforms in the adult and developing human eye. Endocrinology, 1993, 133(2), 600-7.
108. Ban, Y.; Rizzolo, L. J. Regulation of glucose transporters during development of the retinal pigment epithelium. Brain. Res. Dev. Brain Res., 2000, 121(1), 89-95.
109. Fernandes, R.; Suzuki, K.; Kumagai, A. K. Inner blood-retinal barrier GLUT1 in long-term diabetic rats: an immunogold electron microscopic study. Invest. Ophthalmol. Vis. Sci. 2003, 44(7), 3150-4.
110. Takata, K.; Kasahara, T.; Kasahara, M.; Ezaki, O.; Hirano, H. Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT1) in cells of the blood-retinal barrier in the rat. Invest. Ophthalmol. Vis. Sci., 1992, 33(2), 377-83.
111. Majumdar, S.; Gunda, S.; Mitra, A. Functional expression of a sodium dependent nucleoside transporter on rabbit cornea: Role in corneal permeation of acyclovir and idoxuridine. Curr. Eye Res., 2003, 26(3-4), 175-83.
112. Majumdar, S.; Tirucherai, G. S.; Pal, D.; Mitra, A. K. Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea. AAPS PharmSci., 2003, 5(2), E15.
113. Hosoya, K.; Horibe, Y.; Kim, K. J.; Lee, V. H. Nucleoside transport mechanisms in the pigmented rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci., 1998, 39(2), 372-7.
114. Majumdar, S.; Macha, S.; Pal, D.; Mitra, A. K. Mechanism of ganciclovir uptake by rabbit retina and human retinal pigmented epithelium cell line ARPE-19. Curr. Eye Res., 2004, 29(2-3), 127-36.
115. Williams, E. F.; Ezeonu, I.; Dutt, K. Nucleoside transport sites in a cultured human retinal cell line established by SV-40 T antigen gene. Curr. Eye Res., 1994, 13(2), 109-18.
116. Nagase, K.; Tomi, M.; Tachikawa, M.; Hosoya, K. Functional and molecular characterization of adenosine transport at the rat inner blood-retinal barrier. Biochim. Biophys. Acta., 2006, 1758(1), 13-9.
117. Giasson, C.; Bonanno, J. A. Facilitated transport of lactate by rabbit corneal endothelium. Exp. Eye Res., 1994, 59(1), 73-81.
118. Gerhart, D. Z.; Leino, R. L.; Drewes, L. R. Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience, 1999, 92(1), 367-75.
119. Philp, N. J.; Wang, D.; Yoon, H.; Hjelmeland, L. M. Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells. Invest. Ophthalmol. Vis. Sci., 2003, 44(4), 1716-21.
120. Talluri, R. S.; Katragadda, S.; Pal, D.; Mitra, A. K. Mechanism of L-ascorbic acid uptake by rabbit corneal epithelial cells: evidence for the involvement of sodium-dependent vitamin C transporter 2. Curr. Eye Res., 2006, 31(6), 481-9.
121. Salceda, R.; Contreras-Cubas, C. Ascorbate uptake in normal and diabetic rat retina and retinal pigment epithelium. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 2007, 146(1-2), 175-9.
122. Khatami, M.; Stramm, L. E.; Rockey, J. H. Ascorbate transport in cultured cat retinal pigment epithelial cells. Exp. Eye. Res., 1986, 43(4), 607-15.
123. Hosoya, K.; Minamizono, A.; Katayama, K.; Terasaki, T.; Tomi, M. Vitamin C transport in oxidized form across the rat bloodretinal barrier. Invest. Ophthalmol. Vis. Sci., 2004, 45(4), 1232-9.
124. Janoria, K. G.; Hariharan, S.; Paturi, D.; Pal, D.; Mitra, A. K. Biotin uptake by rabbit corneal epithelial cells: role of sodiumdependent multivitamin transporter (SMVT). Curr. Eye Res., 2006, 31(10), 797-809.
125. Ohkura, Y.; Akanuma, S.; Tachikawa, M.; Hosoya, K. Blood-toretina transport of biotin via Na+-dependent multivitamin transporter (SMVT) at the inner blood-retinal barrier. Exp. Eye Res., 2010, 91(3), 387-92.
126. Hariharan, S.; Janoria, K. G.; Gunda, S.; Zhu, X.; Pal, D.; Mitra, A. K. Identification and functional expression of a carrier-mediated riboflavin transport system on rabbit corneal epithelium. Curr. Eye. Res., 2006, 31(10), 811-24.
127. Kansara, V.; Pal, D.; Jain, R.; Mitra, A. K. Identification and functional characterization of riboflavin transporter in human-derived retinoblastoma cell line (Y-79): mechanisms of cellular uptake and translocation. J. Ocul. Pharmacol. Ther., 2005, 21(4), 275-87.
128. Said, H. M.; Wang, S.; Ma, T. Y. Mechanism of riboflavin uptake by cultured human retinal pigment epithelial ARPE-19 cells: possible regulation by an intracellular Ca2+-calmodulin-mediated pathway. J. Physiol., 2005, 566(Pt 2), 369-77.
129. Jain-Vakkalagadda, B.; Dey, S.; Pal, D.; Mitra, A. K. Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest. Ophthalmol. Vis. Sci., 2003, 44(7), 2919-27.
130. Pow, D. V. Amino acids and their transporters in the retina. Neurochem. Int., 2001, 38(6), 463-84.
131. Gandhi, M. D.; Pal, D.; Mitra, A. K. Identification and functional characterization of a Na (+)-independent large neutral amino acid transporter (LAT2) on ARPE-19 cells. Int. J. Pharm., 2004, 275, (1-2), 189-200.
132. Tomi, M.; Mori, M.; Tachikawa, M.; Katayama, K.; Terasaki, T.; Hosoya, K. L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier. Invest. Ophthalmol. Vis. Sci., 2005, 46(7), 2522-30.
133. Katragadda, S.; Talluri, R. S.; Pal, D.; Mitra, A. K. Identification and characterization of a Na+-dependent neutral amino acid transporter, ASCT1, in rabbit corneal epithelial cell culture and rabbit cornea. Curr. Eye Res., 2005, 30(11), 989-1002.
134. Yoneyama, D.; Shinozaki, Y.; Lu, W. L.; Tomi, M.; Tachikawa, M.; Hosoya, K. Involvement of system A in the retina-to-blood transport of l-proline across the inner blood-retinal barrier. Exp. Eye Res., 2010, 90(4), 507-13.
135. Jain-Vakkalagadda, B.; Pal, D.; Gunda, S.; Nashed, Y.; Ganapathy, V.; Mitra, A. K. Identification of a Na+-dependent cationic and neutral amino acid transporter, B (0, +), in human and rabbit cornea. Mol. Pharm., 2004, 1(5), 338-46.
136. Hosoya, K.; Horibe, Y.; Kim, K. J.; Lee, V. H. Na (+)-dependent Larginine transport in the pigmented rabbit conjunctiva. Exp. Eye Res., 1997, 65(4), 547-53.
137. Kompella, U. B.; Kim, K. J.; Shiue, M. H.; Lee, V. H. Possible existence of Na (+)-coupled amino acid transport in the pigmented rabbit conjunctiva. Life Sci., 1995, 57(15), 1427-31.
138. Jager, K.; Bonisch, U.; Risch, M.; Worlitzsch, D.; Paulsen, F. Detection and regulation of cationic amino acid transporters in healthy and diseased ocular surface. Invest. Ophthalmol. Vis. Sci., 2009, 50(3), 1112-21.
139. Tornquist, P.; Alm, A. Carrier-mediated transport of amino acids through the blood-retinal and the blood-brain barriers. Graefes. Arch. Clin. Exp. Ophthalmol., 1986, 224(1), 21-5.
140. Kansara, V.; Mitra, A. K. Evaluation of an ex vivo model implication for carrier-mediated retinal drug delivery. Curr. Eye Res., 2006, 31(5), 415-26.
141. Chancy, C. D.; Kekuda, R.; Huang, W.; Prasad, P. D.; Kuhnel, J. M.; Sirotnak, F. M.; Roon, P.; Ganapathy, V.; Smith, S. B. Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J. Biol. Chem., 2000, 275(27), 20676-84.
142. Huang, W.; Prasad, P. D.; Kekuda, R.; Leibach, F. H.; Ganapathy, V. Characterization of N5-methyltetrahydrofolate uptake in cultured human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci., 1997, 38(8), 1578-87.
143. Hosoya, K.; Fujita, K.; Tachikawa, M. Involvement of reduced folate carrier 1 in the inner blood-retinal barrier transport of methyltetrahydrofolate. Drug Metab. Pharmacokinet., 2008, 23(4), 285-92.
144. Bozard, B. R.; Ganapathy, P. S.; Duplantier, J.; Mysona, B.; Ha, Y.; Roon, P.; Smith, R.; Goldman, I. D.; Prasad, P.; Martin, P. M.; Ganapathy, V.; Smith, S. B. Molecular and biochemical characterization of folate transport proteins in retinal Muller cells. Invest. Ophthalmol. Vis. Sci., 2010, 51(6), 3226-35.
145. Umapathy, N. S.; Gnana-Prakasam, J. P.; Martin, P. M.; Mysona, B.; Dun, Y.; Smith, S. B.; Ganapathy, V.; Prasad, P. D. Cloning and functional characterization of the proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell types. Invest. Ophthalmol. Vis. Sci., 2007, 48(11), 5299-305.
146. Smith, S. B.; Kekuda, R.; Gu, X.; Chancy, C.; Conway, S. J.; Ganapathy, V. Expression of folate receptor alpha in the mammalian retinol pigmented epithelium and retina. Invest. Ophthalmol. Vis. Sci., 1999, 40(5), 840-8.
147. Baudouin, C.; Brignole, F.; Fredj-Reygrobellet, D.; Negre, F.; Bayle, J.; Gastaud, P. Transferrin receptor expression by retinal pigment epithelial cells in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci., 1992, 33(10), 2822-9.
148. Kompella, U. B.; Sundaram, S.; Raghava, S.; Escobar, E. R. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol. Vis., 2006, 12, 1185-98.
149. Yefimova, M. G.; Jeanny, J. C.; Guillonneau, X.; Keller, N.; Nguyen-Legros, J.; Sergeant, C.; Guillou, F.; Courtois, Y. Iron, ferritin, transferrin, and transferrin receptor in the adult rat retina. Invest. Ophthalmol. Vis. Sci., 2000, 41(8), 2343-51.
150. Gnana-Prakasam, J. P.; Martin, P. M.; Smith, S. B.; Ganapathy, V. Expression and function of iron-regulatory proteins in retina. IUBMB Life, 2010, 62(5), 363-70.
151. Dey, S.; Patel, J.; Anand, B. S.; Jain-Vakkalagadda, B.; Kaliki, P.; Pal, D.; Ganapathy, V.; Mitra, A. K. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Vis. Sci., 2003, 44(7), 2909-18.
152. Saha, P.; Yang, J. J.; Lee, V. H. Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells. Invest. Ophthalmol. Vis. Sci., 1998, 39(7), 1221-6.
153. Maines, L. W.; Antonetti, D. A.; Wolpert, E. B.; Smith, C. D. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology, 2005, 49(5), 610-7.
154. Mannermaa, E.; Vellonen, K. S.; Ryhanen, T.; Kokkonen, K.; Ranta, V. P.; Kaarniranta, K.; Urtti, A. Efflux protein expression in human retinal pigment epithelium cell lines. Pharm. Res., 2009, 26(7), 1785-91.
155. Kennedy, B. G.; Mangini, N. J. P-glycoprotein expression in human retinal pigment epithelium. Mol. Vis., 2002, 8, 422-30.
156. Tagami, M.; Kusuhara, S.; Honda, S.; Tsukahara, Y.; Negi, A. Expression of ATP-binding cassette transporters at the inner bloodretinal barrier in a neonatal mouse model of oxygen-induced retinopathy. Brain Res., 2009, 1283, 186-93.
157. Karla, P. K.; Pal, D.; Quinn, T.; Mitra, A. K. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int. J. Pharm., 2007, 336(1), 12-21.
158. Vellonen, K. S.; Mannermaa, E.; Turner, H.; Hakli, M.; Wolosin, J. M.; Tervo, T.; Honkakoski, P.; Urtti, A. Effluxing ABC transporters in human corneal epithelium. J. Pharm. Sci., 2010, 99(2), 1087-98.
159. Karla, P. K.; Earla, R.; Boddu, S. H.; Johnston, T. P.; Pal, D.; Mitra, A. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr. Eye Res., 2009, 34(1), 1-9.
160. Dal Pozzo, F.; Andrei, G.; Lebeau, I.; Beadle, J. R.; Hostetler, K. Y.; De Clercq, E.; Snoeck, R. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral. Res., 2007, 75(1), 52-7.
161. anoria, K. G.; Gunda, S.; Boddu, S. H.; Mitra, A. K. Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv., 2007, 4(4), 371-88.
162. Anand, B. S.; Katragadda, S.; Mitra, A. K. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J. Pharmacol. Exp. Ther., 2004, 311(2), 659-67.
163. Anand, B. S.; Hill, J. M.; Dey, S.; Maruyama, K.; Bhattacharjee, P. S.; Myles, M. E.; Nashed, Y. E.; Mitra, A. K. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest. Ophthalmol. Vis. Sci., 2003, 44(6), 2529-34.
164. Anand, B. S.; Dey, S.; Mitra, A. K. Current prodrug strategies via membrane transporters/receptors. Expert Opin. Biol. Ther., 2002, 2(6), 607-20.
165. Granero, G. E.; Amidon, G. L. Stability of valacyclovir: implications for its oral bioavailability. Int. J. Pharm., 2006, 317(1), 14-8.
166. Soul-Lawton, J.; Seaber, E.; On, N.; Wootton, R.; Rolan, P.; Posner, J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother., 1995, 39(12), 2759-64.
167. Talluri, R. S.; Samanta, S. K.; Gaudana, R.; Mitra, A. K. Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir. Int. J. Pharm., 2008, 361(1-2), 118-24.
168. Friedrichsen, G. M.; Jakobsen, P.; Taub, M.; Begtrup, M. Application of enzymatically stable dipeptides for enhancement of intestinal permeability. Synthesis and in vitro evaluation of dipeptidecoupled compounds. Bioorg. Med. Chem., 2001, 9(10), 2625-32.
169. Steffansen, B.; Lepist, E. I.; Taub, M. E.; Larsen, B. D.; Frokjaer, S.; Lennernas, H. Stability, metabolism and transport of DAsp (OBzl)-Ala-a model prodrug with affinity for the oligopeptide transporter. Eur. J. Pharm. Sci., 1999, 8(1), 67-73.
170. Tamura, K.; Lee, C. P.; Smith, P. L.; Borchardt, R. T. Metabolism, uptake, and transepithelial transport of the stereoisomers of Val Val-Val in the human intestinal cell line, Caco-2. Pharm. Res., 1996, 13(11), 1663-7.
171. Talluri, R. S.; Gaudana, R.; Hariharan, S.; Mitra, A. K. Pharmacokinetics of stereoisomeric dipeptide prodrugs of acyclovir following intravenous and oral administrations in rats: a study involving in vivo corneal uptake of acyclovir following oral dosing. Ophthalmol. Eye Dis., 2009, 1, 21-31.
172. Gaudana, R.; Jwala, J.; Boddu, S. H.; Mitra, A. K. Recent perspectives in ocular drug delivery. Pharm. Res., 2009, 26(5), 1197-216.
173. Cheng, L.; Hostetler, K. Y.; Lee, J.; Koh, H. J.; Beadle, J. R.; Bessho, K.; Toyoguchi, M.; Aldern, K.; Bovet, J. M.; Freeman, W. R. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest. Ophthalmol. Vis. Sci., 2004, 45(11), 4138-44.
174. Bidanset, D. J.; Beadle, J. R.; Wan, W. B.; Hostetler, K. Y.; Kern, E. R. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J. Infect. Dis., 2004, 190(3), 499-503.
175. Charteris, D. G.; Aylward, G. W.; Wong, D.; Groenewald, C.; Asaria, R. H.; Bunce, C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology, 2004, 111(12), 2240-5.
176. Cardillo, J. A.; Farah, M. E.; Mitre, J.; Morales, P. H.; Costa, R. A.; Melo, L. A.; Kuppermann, B.; Jorge, R.; Ashton, P. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br. J. Ophthalmol., 2004, 88(9), 1201-5.
177. Cheng, L.; Hostetler, K.; Valiaeva, N.; Tammewar, A.; Freeman, W. R.; Beadle, J.; Bartsch, D. U.; Aldern, K.; Falkenstein, I. Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest. Ophthalmol. Vis. Sci., 2010, 51(1), 474-81.
178. Randhawa, P.; Farasati, N. A.; Shapiro, R.; Hostetler, K. Y. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob. Agents Chemother., 2006, 50(4), 1564-6.
179. Williams-Aziz, S. L.; Hartline, C. B.; Harden, E. A.; Daily, S. L.; Prichard, M. N.; Kushner, N. L.; Beadle, J. R.; Wan, W. B.; Hostetler, K. Y.; Kern, E. R. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother., 2005, 49(9), 3724-33.
180. Hartline, C. B.; Gustin, K. M.; Wan, W. B.; Ciesla, S. L.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J. Infect. Dis., 2005, 191(3), 396-9.
181. Buller, R. M.; Owens, G.; Schriewer, J.; Melman, L.; Beadle, J. R.; Hostetler, K. Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology, 2004, 318(2), 474-81.
182. Beadle, J. R.; Hartline, C.; Aldern, K. A.; Rodriguez, N.; Harden, E.; Kern, E. R.; Hostetler, K. Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents. Chemother., 2002, 46(8), 2381-6.
183. Kern, E. R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J. R.; Hostetler, K. Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother., 2002, 46(4), 991-5.
184. Cheng, L.; Hostetler, K. Y.; Chaidhawangul, S.; Gardner, M. F.; Beadle, J. R.; Keefe, K. S.; Bergeron-Lynn, G.; Severson, G. M.; Soules, K. A.; Mueller, A. J.; Freeman, W. R. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest. Ophthalmol. Vis. Sci., 2000, 41(6), 1523-32.
185. Andrei, G.; Snoeck, R.; Neyts, J.; Sandvold, M. L.; Myhren, F.; De Clercq, E. Antiviral activity of ganciclovir elaidic acid ester against herpesviruses. Antiviral. Res., 2000, 45(3), 157-67.
186. Cheng, L.; Hostetler, K. Y.; Gardner, M. F.; Avila, C. P., Jr.; Bergeron-Lynn, G.; Severson, G. M.; Freeman, W. R. Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-Ooctadecylsn-glycerol-3- phosphonoformate (ODG-PFA). Curr. Eye Res., 1999, 18(3), 161-7.
187. Koppelhus, U.; Shiraishi, T.; Zachar, V.; Pankratova, S.; Nielsen, P. E. Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. Bioconjug. Chem., 2008, 19(8), 1526-34.
188. Hughes, P. M.; Olejnik, O.; Chang-lin, J. Compositions and methods for the intraocular transport of therapeutic agents. U. S. Patent 7714024, 2007.
189. Garst, M. E.; Adorante, J. S. Methods and compositions for drug delivery. U. S. Patent 6350780, 2002.
190. Marcus, D. M.; Chu, C. K. Methods and compositions for treatment of macular and retinal disease. U. S. Patent 20070259843, 2007.
191. Rabinovich-guilatt, L.; Lambert, G. Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye. U. S. Patent 20070280995, 2007.
192. Prokai, L.; Prokai, K.; Simpkins, J. Agarwal, N. Prodrugs for use as ophthalmic agents. U. S. Patent 7572781, 2007.
193. Rothbard, J. B.; Wender, P. A.; McGrane, L. P.; Sista V, L. S.; Kirschberg, T. A. Compositions and methods for enhancing drug delivery across and into ocular tissues. U. S. Patent 7229961, 2007.
194. Dalpiaz, A.; Cacciari, B.; Mezzena, M.; Strada, M.; Scalia, S. Solid lipid microparticles for the stability enhancement of a dopamine prodrug. J. Pharm. Sci., 2010, 99(11), 4730-7.
195. wala, J.; Boddu, S. H.; Shah, S.; Sirimulla, S.; Pal, D.; Mitra, A. K. Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir. J. Ocul. Pharmacol. Ther., 2011, 27(2), 163-72.
196. Kawakami, S.; Yamamura, K.; Mukai, T.; Nishida, K.; Nakamura, J.; Sakaeda, T.; Nakashima, M.; Sasaki, H. Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J. Pharm. Pharmacol., 2001, 53(8), 1157-61.
197. Barot. M.; Gokulgandhi, M. R.; Mitra, A. K. Mitochondrial dysfunction in retinal Curr. Eye Res., 2011, 36(12), 1069-77.